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Impact of KRAS mutation status
on the efficacy of immunotherapy
in lung cancer brain metastases
Adam Lauko1, Rupesh Kotecha2,3, Addison Barnett4, Hong Li5, Vineeth Tatineni6,
Assad Ali4, Pradnya Patil7, Alireza M. Mohammadi1,4,8, Samuel T. Chao4,9, Erin S. Murphy4,9,
Lilyana Angelov1,4,8, John H. Suh4,9, Gene H. Barnett1,4,8, Nathan A. Pennell7 &
Manmeet S. Ahluwalia3,10*
Immune checkpoint inhibitors (ICIs) have resulted in improved outcomes in non-small cell lung cancer
(NSCLC) patients. However, data demonstrating the efficacy of ICIs in NSCLC brain metastases
(NSCLCBM) is limited. We analyzed overall survival (OS) in patients with NSCLCBM treated with ICIs
within 90 days of NSCLCBM diagnosis (ICI-90) and compared them to patients who never received ICIs
(no-ICI). We reviewed 800 patients with LCBM who were diagnosed between 2010 and 2019 at a major
tertiary care institution, 97% of whom received stereotactic radiosurgery (SRS) for local treatment
of BM. OS from BM was compared between the ICI-90 and no-ICI groups using the Log-Rank test and
Cox proportional-hazards model. Additionally, the impact of KRAS mutational status on the efficacy
of ICI was investigated. After accounting for known prognostic factors, ICI-90 in addition to SRS led
to significantly improved OS compared to no-ICI (12.5 months vs 9.1, p < 0.001). In the 109 patients
who had both a known PD-L1 expression and KRAS status, 80.4% of patients with KRAS mutation had
PD-L1 expression vs 61.9% in wild-type KRAS patients (p = 0.04). In patients without a KRAS mutation,
there was no difference in OS between the ICI-90 vs no-ICI cohort with a one-year survival of 60.2% vs
54.8% (p = 0.84). However, in patients with a KRAS mutation, ICI-90 led to a one-year survival of 60.4%
vs 34.1% (p = 0.004). Patients with NSCLCBM who received ICI-90 had improved OS compared to no-ICI
patients. Additionally, this benefit appears to be observed primarily in patients with KRAS mutations
that may drive the overall benefit, which should be taken into account in the development of future
trials.
Lung cancer is the most common primary tumor that metastasizes to the brain, accounting for approximately
50% of brain metastases (BM)1. For patients without actionable mutations, systemic chemotherapy has shown
little intracranial efficacy, and traditionally, non-small cell lung cancer (NSCLC) BM have been managed with
local treatments, such as resection and radiotherapy.
Exciting developments in cancer therapeutics targeting the PD-1 or PD-L1 axis have led to the approval of
multiple immune checkpoint inhibitors (ICIs) as standard of care options in the first line setting2 and as salvage
options after failure of first-line c hemotherapy3. However, given the historically poor prognosis of patients with
NSCLCBM, these patients were excluded from many of the initial trials unless they had previously treated and
stable intracranial d
 isease2–4. Recently, several retrospective series and a single center phase 2 clinical trial have
demonstrated limited intracranial efficacy with ICIs alone, ranging from 12 to 40%5–7. Additionally, there is
newer evidence that a combination approach with stereotactic radiosurgery (SRS) and ICI may be more beneficial
for intracranial control, as this has been shown to have better intracranial response over either therapy a lone8.
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Additionally, many researchers are interested in possible increased rates of the abscopal effect when fractional
dose radiation and ICIs are given c oncordantly9.
KRAS mutations are present in approximately 30% of NSCLC adenocarcinomas and have been associated
with a poorer prognosis when compared to wild-type t umors10–12. Until May 2021, there was no FDA approved
targeted therapies towards KRAS mutations for patients with NSCLC. Patients frequently receive ICIs as standardof-care treatments based on PD-L1 expression, regardless of KRAS mutation status. There is also evidence that
KRAS mutations lead to increased expression of PD-L1, a known predictor of response to ICIs13,14; however,
impact of KRAS mutation status on treatment outcome for patients with NSCLCBM has yet to be empirically
demonstrated.
In this study, we analyzed a large population of patients with NSCLCBM who were treated at a single tertiary
center. We compared the survival of those who received ICI after the diagnosis of BM to those who did not
receive ICI within this timeframe. Additionally, the impact of KRAS mutation status on the efficacy of ICI was
investigated. We hypothesized that patients treated with ICIs after the diagnosis of BM would have an improved
survival and that within the ICI group, those with KRAS mutations would have improved survival over those
with KRAS wild-type disease.

Methods

Patient selection and treatment. This retrospective cohort study included patients treated for
NSCLCBM at a single tertiary care center from 2010 to 2019. This study was approved by the Cleveland Clinic
Foundation institutional review board and received an informed consent waiver due to the retrospective nature
of the study. All methods were carried out in accordance with relevant guidelines and regulations. Patient characteristics, diagnostic information, and treatment details were abstracted from the shared electronic medical
record.
All the patients’ treatments were extracted after diagnosis of the primary cancer. This included SRS, wholebrain radiation therapy (WBRT), surgery, as well as any systemic therapies, including targeted therapies, chemotherapy, and ICI. Patients’ PD-L1 expression were extracted from pathology reports of tissue, primarily from
the lung. Patients who had documented EGFR or ALK mutations who received a targeted therapy towards these
mutations were excluded from this analysis. Patients who underwent resection of their intracranial tumors or
diagnosed with small cell lung cancer were also excluded. All treatment decisions were made by the multidisciplinary team and were based on current national guideline standards at the time. Dosing schedule for Nivolumab
was 3 mg/kg or 240 mg flat dose every other week and 2 mg/kg or 200 mg flat does every three weeks or 400 mg
flat dose every six weeks for pembrolizumab.
Patients were divided into three groups based on if and when they were treated with ICIs. Those treated with
ICIs within 90 days of the diagnosis of BM were classified as ICI-90, and those treated with ICI greater than
90 days after diagnosis of BM were classified as G90. Patients who did not receive ICI after diagnosis of BM at
any point were classified as no-ICI.
Outcome measures. Overall survival (OS) was determined from the date of diagnosis of BM until the
date of death. Patients who were still alive at the day of collection or lost to follow-up were censored at the last
follow-up date.
Statistical analysis. All variables included in this analysis had < 5% missing except for Karnofsky Perfor-

mance Status (KPS) at diagnosis (15% missing). Several numerical variables were also grouped as categorical and
both their numerical and categorical forms were evaluated. This included age (< 65 and ≥ 65), number of SRS
treatments (0–1 and ≥ 2) (only 3% of patients did not receive SRS), lesion number at diagnosis (1 and ≥ 2) and
KPS (< 90 and ≥ 90). Patient demographic and clinical characteristics were compared using Chi-square test for
categorical variables and Kruskal–Wallis test for numerical variables. If any differences between the three groups
were detected, no-ICI and ICI-90 were then compared. Times from BM diagnosis to death or last contact were
calculated for OS analysis. Patients who died after 2 years or followed more than 2 years were censored at 2 years.
Patient demographics and clinical characteristics that were potentially associated with OS (p < 0.05) among
BM patients who did not have surgery were identified in univariate analysis using Kaplan–Meier method and
simple Cox hazard models. Since identified factors potentially associated with OS were previously reported to
associate with survival or commonly included in lung cancer BM s tudies15, they were included in the multivariate analysis of OS between ICI-90 and no ICI. A 1:1 propensity score (PS) matched analysis between no-ICI and
ICI-90 was also performed to correct potential treatment selection biases. The matched pairs were identified from
a logistic regression model with the Greedy method that included age, KPS, extracranial metastases (EC-mets),
lesion number, and SRS number with exact match on EC-mets. Kaplan–Meier method was utilized to compare
OS between matched ICI-90 and no-ICI group.
A secondary analysis explored ICI effect on OS by KRAS status. Among patients who had a known KRAS
mutation status, Cox proportional hazard model with an ICI-KRAS interaction term was utilized to determine
the impact of KRAS mutation status on ICI efficacy.
All analyses were performed using SAS version 9.4, two-sided p values are presented. A p < 0.05 was considered as statistically significant.

Results

Patient characteristics. A total of 800 patients were diagnosed with lung cancer BM at our tertiary center

between 2010 and 2019. Ninety-seven percent of the patients in this cohort received SRS for intracranial treatment of BM. One hundred and thirty-three patients with small cell lung cancer or NSCLC that was treated with
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Factor

Total (N = 521)

No-ICI (N = 325)

ICI-90 (N = 68)

G90 (N = 128)

p value overall/No-ICI vs
IC-I90

Age

62.7 [56.9, 70.6]

63.0 [57.1, 70.7]

60.4 [54.1, 70.3]

62.2 [57.1, 70.3]

0.29

Age, ≥ 65

214 (41.1)

139 (42.8)

22 (32.4)

53 (41.4)

0.28

Sex: male

262 (50.3)

174 (53.5)

32 (47.1)

56 (43.8)

0.15

Race: white

439 (84.3)

272 (83.7)

55 (80.9)

112 (87.5)

0.43

KPS

80.0 [80.0, 90.0]

80.0 [70.0, 90.0]

80.0 [70.0, 90.0]

90.0 [80.0, 90.0]

< 0.001/0.86

< 90

221 (42.4)

140 (43.1)

38 (55.9)

43 (33.6)

≥ 90

220 (42.2)

112 (34.5)

29 (42.6)

79 (61.7)

Unknown

80 (15.4)

73 (22.5)

1 (1.5)

6 (4.7)

Lesion number

2.0 [1.00, 3.0]

1.00 [1.00, 3.0]

2.0 [1.00, 3.0]

2.0 [1.00, 3.0]

0.27

Lesion ≥ 2

261 (50.3)

153 (47.4)

37 (54.4)

71 (55.5)

0.23

Number of SRS

1.00 [1.00, 2.0]

1.00 [1.00, 2.0]

1.00 [1.00, 2.0]

2.0 [1.00, 2.0]

< 0.001/0.64

SRS ≥ 2

164 (32.2)

81 (25.7)

17 (25.4)

66 (52.0)

< 0.001

Histology: adenocarcinoma

371 (73.9)

216 (70.6)

52 (76.5)

103 (80.5)

0.089

EC-mets

238 (46.6)

139 (44.0)

37 (55.2)

62 (48.4)

0.22

WBRT

131 (25.1)

86 (26.5)

11 (16.2)

34 (26.6)

0.19

Negative

109 (20.9)

50 (15.4)

16 (23.5)

43 (33.6)

Positive

98 (18.8)

39 (12.0)

23 (33.8)

36 (28.1)

Missing

314 (60.3)

236 (72.6)

29 (42.6)

49 (38.3)

Negative

30 (5.8)

16 (4.9)

4 (5.9)

10 (7.8)

Positive

93 (17.9)

27 (8.3)

40 (58.8)

26 (20.3)

Missing

398 (76.4)

282 (86.8)

24 (35.3)

92 (71.9)

< 0.001

KPS ≥ 90

< 0.001/< 0.001

KRAS status

< 0.001/< 0.001

PDL1 status

Table 1.  Patient characteristics at diagnosis of brain metastasis. Data not available for all subjects. Missing
values: KPS = 80, lesion number = 2, srs number = 12, Histology = 19, Extracranial Metastases = 10. Statistics
presented as Median [P25, P75] or N (column %). Significant differences (p < 0.05) are bolded.

targeted therapy against an EGFR mutation or ALK translocations were excluded from the analysis, leaving
667 patients. Additionally, 146 patients underwent an intracranial tumor resection, with four of these patients
receiving ICIs versus 142 never receiving ICIs. Because of this heavily skewed distribution, these patients were
excluded as well. This left 521 patients with the general characteristics outlined in Table 1. Twenty-five percent
(n = 128) of patients received ICI greater than 90 days after the diagnosis of BM, 13% (n = 68) received ICI within
90 days of diagnosis of BM, and 62% (n = 325) of patients never received ICI (Fig. 1).
Patient characteristics between those receiving ICI compared to those who never received ICI are outlined
in Table 1. There was no statistical difference in age, sex, or race between the two groups (p > 0.05). The median
KPS at diagnosis was 80 for both groups. The median number of lesions at the diagnosis of BM was 1 in no-ICI
group and 2 in the ICI-90, however this variance was not statistically different (p = 0.27). Of the patients in the
ICI-90 cohort, 55.2% had an EC-mets compared to only 44.0% in the no-ICI group.
Demographics and clinical factors that may associate with OS were first identified by univariate analysis
across the 521 patients. KPS below 90 (p < 0.001), age older than 65 (p = 0.005), presence of EC-mets at diagnosis of BM (p = 0.02), adenocarcinoma histology (p < 0.001), and male sex (p = 0.02) were significant predictors
of worse OS. However, the number of intracranial lesions at diagnosis of BM was not found to be statistically
significant (p = 0.72) (Table 2).

ICI within 90 days. Overall survival from the time of diagnosis of BM was compared between those treated

without ICI and those treated with ICI within the first 90 days. On univariable analysis, there was a significant
difference in OS between the groups with median survival of 9.1 months and 12.5 months, respectively (p = 0.04)
(Fig. 2A). In a multivariate analysis, treatment with ICI-90 led to significantly improved OS (p < 0.001) (Table 3).
A similar analysis was performed excluding patients with missing KPS, and ICI-90 remained a significant predictor of OS (p = 0.001).
Additionally, a PS matching was performed to select patients who did not receive ICIs with similar characteristics to the ICI-90 cohort. When both groups were matched to have similar age, KPS, EC-mets (exact match),
number of lesions, and number of SRS treatments, there was almost a 5-month median survival advantage with
ICIs within 90 days (12.5 vs 7.8 months, p = 0.005) (Fig. 2B).

Impact of KRAS mutation status on the efficacy of ICI.

Given the emerging data regarding presence of KRAS mutation and response to ICI, we first analyzed the expression of PD-L1 based on KRAS mutation status. Out of 800 total patients diagnosed with LCBM, 109 patients had both a known PD-L1 expression
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Figure 1.  Flow chart of the study population. ICI = immune checkpoint inhibitor; BM = Brain Metastases;
LCBM = lung cancer brain metastases.

and KRAS status. PD-L1 was expressed in 80.4% of patients with KRAS mutation vs. 61.9% of KRAS wild-type
patients (p = 0.04).
We then compared OS from the time of BM between those not treated with ICIs vs. those treated with ICIs
(Fig. 3). In patients without KRAS mutations, there was no statistical difference in OS between the ICI vs. no ICI
cohorts with a one-year survival of 60.2% vs 54.8% (adjusted p = 0.84). However, in patients with KRAS mutations,
patient treated with ICIs had a 1-year survival of 60.4% vs. 34.1% in the no-ICI cohort. On multivariate analysis
including age, gender, SRS, histology, KPS, number of lesions, and presence of EC-mets, these results remained
consistent and statistically significant (p = 0.004). When comparing all patients who received ICIs, there was no
difference in OS from BM between patients with vs without KRAS mutations.

Discussion

Patients with NSCLCBM have a poor prognosis and traditional systemic chemotherapies have provided limited
clinical benefit. With advances in targeted therapies and ICI, this dogma is beginning to shift dramatically. While
some clinical data is available suggesting the efficacy of ICIs in patients with stable, asymptomatic brain metastases, there is almost no prospective or retrospective data in patients with progressive or symptomatic disease. Our
study retrospectively analyzed patients treated for NSCLCBM at a single tertiary care center and compared those
treated with ICIs to those who were not. In agreement with the clinical trials, we observed an improvement in
OS when patients were treated with ICIs within 90 days of the diagnosis of brain metastases (p < 0.0001)2–4. This
data suggests that ICIs provide an OS benefit over traditional chemotherapy or local therapy alone.
Surgery has long been a mainstay of BM treatment, however, advances in SRS have decreased its utilization.
While investigating the prevalence of surgical resection was not the primary goal of this study, when we compared
our ICI-90 cohort to our no-ICI cohort we found a large difference in the proportion who underwent resection of
a BM (29.4% vs 5.7%, p < 0.001) and therefore we excluded these patients from the remaining analyses. Advances
in SRS technology more readily allow for the targeting of multiple intracranial lesions, deep-seated tumors, in
patients who are too frail for surgery, have multiple medical co-morbidities, and is also commonly used in the
salvage setting16,17. These improvements may account for the number of intracranial lesions not predicting OS
within our cohort (hazard ratio of 0.99, p = 0.72). Newer prospective clinical trials are beginning to demonstrate
that patients with multiple lesions can be treated with SRS and have improved intracranial control18. Our cohort
provides additional retrospective evidence that number of lesions may not influence OS when all lesions are
treated with SRS18,19. With that being said, other variables that have previously been reported, such as EC-mets,
age and KPS all predicted O
 S15,20.
In order to identify patient populations who respond best to ICIs, we investigated the impact of KRAS mutation status. We found an improved OS in patients with a KRAS mutation who were treated with ICI within 90 days
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Variable

N

Events

Median months

1-Year survival % (95% CI)

Sex

Cox univariate hazard ratio
(95% CI)

Cox univariate Wald p-value

0.023

Female

259

157 (61%)

13.4

58.4 (52.3, 64.5)

Male

262

178 (68%)

11.1

48.6 (42.4, 54.8)

Race

–
1.28 (1.03, 1.59)

0.024

0.75

Non-white
White

log-rank p value

82

51 (62%)

12.3

52.0 (40.9, 63.1)

439

284 (65%)

12.7

53.8 (49.0, 58.5)

Age

–
0.95 (0.71, 1.28)

0.75

0.005

< 65

307

186 (61%)

13.8

56.8 (51.1, 62.4)

≥ 65

214

149 (70%)

10.5

48.8 (42.0, 55.6)

KPS

–
1.36 (1.10, 1.69)

0.005
< 0.001

< 0.001

< 90

221

157 (71%)

8.9

40.8 (34.2, 47.4)

1.97 (1.55, 2.50)

≥ 90

220

119 (54%)

18.4

66.8 (60.5, 73.1)

–

80

59 (74%)

12.1

51.3 (40.0, 62.6)

Missing
Lesion number

1.65 (1.21, 2.26)

0.002

0.49

1

258

160 (62%)

13.3

55.7 (49.4, 61.9)

≥2

261

173 (66%)

12.3

51.4 (45.2, 57.6)

SRS

–
1.08 (0.87, 1.34)

0.49

< 0.001

0–1

345

245 (71%)

9.8

43.4 (38.1, 48.8)

≥2

164

82 (50%)

21.7

75.1 (68.4, 81.8)

Histology

–
0.45 (0.35, 0.58)

< 0.001

< 0.001

Other

131

100 (76%)

9.1

38.7 (30.1, 47.3)

Adenocarcinoma

371

221 (60%)

15.0

58.4 (53.3, 63.5)

EC-mets

–
0.57 (0.45, 0.72)

< 0.001

0.018

No

273

166 (61%)

13.9

57.7 (51.7, 63.6)

Yes

238

162 (68%)

10.5

47.9 (41.4, 54.5)

WBRT

–
1.30 (1.04, 1.61)

0.018

0.11

No

390

248 (64%)

12.2

51.0 (45.9, 56.1)

–

Yes

131

87 (66%)

14.9

60.7 (52.3, 69.1)

0.82 (0.64, 1.05)

0.11

Age

521

335 (64%)

12.7

53.5 (49.1, 57.8)

1.014 (1.003, 1.025)

0.012

KPS

441

276 (63%)

12.7

53.8 (49.1, 58.6)

0.96 (0.95, 0.97)

Lesion number

519

333 (64%)

12.7

53.5 (49.1, 57.9)

0.99 (0.96, 1.03)

0.72

SRS

509

327 (64%)

12.7

53.8 (49.4, 58.2)

0.65 (0.57, 0.75)

< 0.001

< 0.001

Table 2.  Univariate analysis of demographics and clinical characteristics. Significant differences (p < 0.05) are
bolded.

Figure 2.  (A) Overall survival comparing ICI-90 to no-ICI with the exclusion of patients who received surgery
for brain metastases. (B) After a Greedy match was performed to balance the ICI-90 and no-ICI cohort after the
removal of patients with intracranial surgery, overall survival from the diagnosis of brain metastases is graphed.
Log-rank test was performed.
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Variable

N

Events

No-ICI

325

247 (76%)

ICI-90

68

39 (57%)

Cox multivariable hazard ratio (95% CI)

Cox multivariable Wald p-value

1.87 (1.30, 2.68)

< 0.001

ICI status
–

Sex
Female

187

130 (70%)

1.02 (0.79, 1.32)

Male

206

156 (76%)

–

0.87

Age
< 65

232

158 (68%)

–

≥ 65

161

128 (80%)

1.302 (1.013, 1.674)

< 90

178

138 (78%)

≥ 90

141

93 (66%)

–

74

55 (74%)

0.93 (0.64, 1.34)

0.69

0–1

284

218 (77%)

2.08 (1.52, 2.85)

< 0.001

≥2

98

60 (61%)

0.039

KPS

Unknown

1.69 (1.28, 2.23)

< 0.001

SRS
–

Histology
Other

106

88 (83%)

Adenocarcinoma

268

184 (69%)

1.39 (1.07, 1.82)

0.014

–

EC-mets
No

207

144 (70%)

–

Yes

176

135 (77%)

1.31 (1.02, 1.68)

0.035

Lesion number
1

201

140 (70%)

–

≥2

190

144 (76%)

1.38 (1.07, 1.78)

0.012

Table 3.  Multivariate analysis on the effect of ICI within 90 days. Significant differences (p < 0.05) are bolded.

Figure 3.  Impact of KRAS status on efficacy of ICI. Overall survival is plotted from the start of ICIs.
Multivariate analysis which included age, gender, SRS, histology, KPS, number of lesions and presence of
EC-mets.
Scientific Reports |
Vol:.(1234567890)

(2021) 11:18174 |

https://doi.org/10.1038/s41598-021-97566-z

6

www.nature.com/scientificreports/
over no-ICI. This difference was not observed in the patients with wild-type KRAS. A similar result was seen in
a meta-analysis of three clinical trials that compared the difference in response to ICIs based on KRAS status21.
Additionally, another recently published study found that patients with KRAS mutations with advanced NSCLC
had improved survival over patients with wild-type KRAS when treated with ICI22. These findings suggest that
while ICIs do not directly target KRAS protein, they may provide significant clinical benefit to these patients.
Additionally, the development of KRAS targeted therapies opens the possibility for combination therapy with
ICIs23. KRAS mutation status should, therefore, be considered in the development of future clinical trials investigating ICIs and BM.
The retrospective nature of the study allows for errors in data collection from an electronic medical record
not designed for research purposes. All our mutation and PD-L1 status was derived from the primary tumor
and KRAS mutational subtypes were not collected. A 2015 study found that all patients with an activating KRAS
mutation in the primary tumor shared this mutation in all clonally related c ases24. Additionally, another recent
study found a 75.5% concordance between PD-L1 expression in primary tumor and BM suggesting that while
PD-L1 status of primary tumor has some predictive value, changes in intracranially do o
 ccur25. Additionally,
although multivariable analysis was performed with known predictors of survival, the cohorts may have differed
in other areas. We were unable to determine whether KRAS mutation status was an independent predictor of
survival or if the increased PD-L1 expression in these patients accounts for the difference. The patients in the
no-ICI group were not necessarily treated with any systemic chemotherapy and almost all received intracranial SRS. Finally, while our study investigated OS after BM, we did not specifically investigate intracranial or
extracranial response, allowing the possibility that any difference in OS may be due to control (or lack thereof)
of extracranial disease.
This study reports a significant survival benefit of ICIs over chemotherapy or local control alone in patients
with NSCLCBM. This retrospective analysis of patients treated for NSCLCBM has also emphasized the shift away
from surgery for management of BM in the age of ICIs. Finally, our data suggests the greatest benefit of ICIs are
seen in patients with KRAS mutations in their tumors, which should be considered in future trials.
Received: 19 May 2021; Accepted: 6 August 2021
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